Hutch News

Hutch News

Stories tagged 'Martin Cheever'

Dr. Carl June weaves together HIV and cancer research to advance cures for both

CAR T-cell pioneer and one-time bone marrow transplant fellow will give keynote at HIV cure conference

Aug. 17, 2017 | By Mary Engel / Fred Hutch News Service

Being in two camps — HIV and cancer research — at one time "made a huge, huge impact on me," says immunotherapy researcher Dr. Carl June.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Feb. 2, 2017

Novel gene therapy for sickle cell disease and related disorders on the horizon; immunotherapy trial in rare skin cancer named one of 2016’s major advances in clinical cancer research and care; Dr. Cara McDermott receives AcademyHealth new investigator award; and study documents sperm changes years after chemotherapy.

View story >


How research and industry partnerships can advance cancer care

Fred Hutch, Merck co-host inaugural ‘Oncology Summit’ to capture non-profit and for-profit outlooks on cancer care

Sept. 27, 2016 | By Rachel Tompa / Fred Hutch News Service

Inaugural 'Oncology Summit,' co-hosted by Fred Hutch and Merck, allowed investors, key players in life sciences to collaborate and share scientific stories.

View story >


'Finally showing hope'

Immunotherapy trial results transforming care for rare skin cancer

April 19, 2016 | By Susan Keown / Fred Hutch News Service

With few remaining options for treating his aggressive Merkel cell carcinoma, Stan Collender joined a clinical trial of the immune-modulating drug pembrolizumab. The trial's results are giving new hope to people with this rare cancer.

View story >


6 questions in cancer immunotherapy

From cancer vaccines to engineered T cells, experts weigh in on the big unknowns

March 18, 2016 | by Susan Keown / Fred Hutch News Service

Fred Hutch immunotherapy experts share their perspectives on a few of the big questions in cancer immunotherapy research — and the steps that they and their colleagues are taking to answer them as quickly as they can.

View story >


Scratching the surface of a rare skin cancer

Immune-boosting therapy shows promise for advanced Merkel cell carcinoma

Oct. 6, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Skin cancer researcher Dr. Paul Nghiem is leading a clinical trial testing the immunotherapy drug pembrolizumab for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Early results from the trial are showing great promise for these patients.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.